Sugi Predict

Sugi Predict / Compounds / SCHEMBL1765701

SCHEMBL1765701

SCHEMBL1765701

CCCC(O)c1ccc(C(=O)OC)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 1/20 0.51
▸ SLC6A4 P31645 1/20 0.51
▸ SLC6A3 Q01959 1/20 0.51
▸ MAPT P10636 2/20 0.49
▸ CA1 P00915 3/20 0.48
▸ CA2 P00918 3/20 0.48
▸ CA12 O43570 2/20 0.48
▸ CA9 Q16790 2/20 0.48
▸ CA14 Q9ULX7 2/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ CA7 P43166 1/20 0.48
▸ LOXL2 Q9Y4K0 1/20 0.47
▸ CYP3A4 P08684 2/20 0.47
▸ CYP2C9 P11712 2/20 0.47
▸ CYP2C19 P33261 2/20 0.47
▸ CYP2D6 P10635 1/20 0.47
▸ HPGD P15428 1/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ KMT2A Q03164 1/20 0.46
▸ TSHR P16473 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14661699 1.00 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3MAPTCA1
SCHEMBL11901631 1.00 SLC6A2 (0.51) SLC6A2SLC6A4SLC6A3MAPTCA1
SCHEMBL1765662 0.92 NPC1 (0.50) SLC6A2SLC6A4SLC6A3MAPTCA1
SCHEMBL1765677 0.90 MGLL (0.50) SLC6A2SLC6A4SLC6A3MAPTCA1
SCHEMBL1765738 0.89 MGLL (0.52) SLC6A2SLC6A4SLC6A3MAPTCA1
SCHEMBL1765727 0.89 MGLL (0.52) SLC6A2SLC6A4SLC6A3MAPTCA1
SCHEMBL3195273 0.86 CYP4A11 (0.51) MAPTCA1CA2CA12CA9
SCHEMBL867166 0.86 CA1 (0.52) MAPTCA1CA2CA12CA9
SCHEMBL25216751 0.85 CYP4A11 (0.58) MAPTCA1CA2CA12CA9
SCHEMBL11962624 0.85 CA1 (0.56) MAPTCA1CA2CA12CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS ITALFARMACO SPA (IT) 2023-09-14 — — US disclosed
CN-109071420-B Amide derivatives, preparation method and medical application thereof 上海昂睿医药技术有限公司 2021-06-18 — — CN disclosed
CN-107235960-B Amide derivatives, preparation method and medical application thereof 浙江海正药业股份有限公司 2021-01-29 — — CN disclosed
CN-109071420-A Amide derivatives, preparation method and medical application thereof 浙江海正药业股份有限公司 2018-12-21 — — CN disclosed
WO-2017215586-A1 AMIDE DERIVATIVES, PREPARATION PROCESS THEREOF AND USE THEREOF IN MEDICINE 浙江海正药业股份有限公司 2017-12-21 — — WO disclosed
CN-107235960-A Amide derivatives, its preparation method and its in purposes pharmaceutically 浙江海正药业股份有限公司 2017-10-10 — — CN disclosed
US-9586931-B2 Triazolyl derivatives as Syk inhibitors MERCK SHARP & DOHME CORP. (US) 2017-03-07 — — US disclosed
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 — — US disclosed
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 — — US disclosed
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS PFIZER INC. (US) 2016-12-15 — — US disclosed
EP-2046755-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. Hoffmann-Roche AG (CH) 2009-04-15 — — EP disclosed
WO-2008012227-A2 PYRAZOLES AS GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2008-01-31 — — WO disclosed
US-20080021032-A1 Pyrazole glucokinase activators BERTHEL STEVEN JOSEPH 2008-01-24 — — US disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US disclosed
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses ELI LILLY AND COMPANY (US) 2007-10-25 — — US disclosed
EP-1758853-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2007-03-07 — — EP disclosed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 — — WO disclosed
WO-2005123668-A1 GLUCAGON RECEPTOR ANTAGONISTS, PREPARATION AND THERAPEUTIC USES ELI LILLY AND COMPANY (US) 2005-12-29 — — WO disclosed
US-4024173-A Process for the manufacture of cyclohexene dicarboxylic acid esters DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) 1977-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230286970-A1 NOVEL OXADIAZOLE-BASED SELECTIVE HDAC6 INHIBITORS HDAC6, HDAC1, HDAC3 SLC6A2 4519/4885SLC6A4 4181/4885SLC6A3 4294/4885
US-20070249688-A1 Glucagon Receptor Antagonists, Preparation and Therapeutic Uses GLP1R, GCGR, GIPR SLC6A2 2317/4885SLC6A4 2988/4885SLC6A3 1907/4885
US-20160362392-A1 GLUCAGON RECEPTOR MODULATORS GLP1R, GCGR, GPR119 SLC6A2 1120/4885SLC6A4 1269/4885SLC6A3 949/4885
US-20080021032-A1 Pyrazole glucokinase activators GCKR, GCK, GALK1 SLC6A2 4146/4885SLC6A4 3293/4885SLC6A3 3386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.